The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
Abstract
A central development of the past decade has been in our understanding of the interactions between, and interdependence of, the innate and adaptive immune responses. Innate immunity recognizes 'danger' signals and activates adaptive immunity in a targeted, appropriate and effective response. Dendritic cells and macrophages have a central role in this process, and pharmacological agents that modulate the functions of these cells could have therapeutic value. The imidazoquinolone compounds, of which imiquimod, formulated as Aldara trade mark, is the best characterized to date, are such molecules. Imiquimod and its homologues act by activating macrophages and other cells via binding to cell surface receptors, such as Toll receptor 7, thereby inducing secretion of pro-inflammatory cytokines, predominantly interferon (IFN)-alpha, tumour necrosis factor (TNF)-alpha and interleukin (IL)-12. This locally generated cytokine milieu biases towards a Th1 cell mediated immune response with the generation of cytotoxic effectors, and this has been exploited clinically in the treatment of viral infections (human papillomavirus, herpes simplex virus, molluscum contagiosum) and nonmelanoma skin cancer. Imiquimod has been shown to be significantly more effective than placebo in clearing genital warts, and mechanism of action studies indicate that this is related to the ability to generate proinflammatory cytokines and a Th1 response. Intra-epithelial neoplasms of cutaneous and mucosal surfaces are associated with human papillomavirus infection and there is some evidence that immune response modifiers may have therapeutic value for these lesions. Topical immunotherapy with immunomodulators shows potential for effective and patient-friendly treatment of cutaneous viral infections. These compounds also have adjuvant properties that could significantly enhance conventional vaccine strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Decoding the Patterns of Self and Nonself by the Innate Immune System
Medzhitov, R., & Janeway, C. A. (2002) · Science · doi:10.1126/science.1068883 · Cited by 2,154
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964
Self-administered Topical 5% Imiquimod Cream for External Anogenital Warts
Edwards, L. (1998) · Archives of Dermatology · doi:10.1001/archderm.134.1.25 · Cited by 559
Immunological Events in Regressing Genital Warts
Coleman, N., Birley, H. D. L., Renton, A. M., Hanna, N. F., Ryait, B. K., Byrne, M., Taylor-Robinson, D., & Stanley, M. A. (1994) · American Journal of Clinical Pathology · doi:10.1093/ajcp/102.6.768 · Cited by 479
Self-citationTherapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
Beutner, K. R., Geisse, J. K., Helman, D., Fox, T. L., Ginkeld, A., & Owens, M. L. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70261-6 · Cited by 363
Marks, R., Gebauer, K., Shumack, S., Amies, M., Bryden, J., Fox, T. L., & Owens, M. L. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.113689 · Cited by 333
Treatment of genital warts with an immune-response modifier (imiquimod)
Beutner, K. R., Spruance, S. L., Hougham, A. J., Fox, T. L., Owens, M. L., & Douglas, J. M. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70243-9 · Cited by 299
Kadowaki, N., Antonenko, S., & Liu, Y.-J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2291 · Cited by 280
Imiquimod 5% cream in the treatment of Bowen's disease
MacKenzie‐Wood, A. R., Kossard, S., de Launey, J. W., Wilkinson, B., & Owens, M. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.111335 · Cited by 273
Cytokine induction by the immunomodulators imiquimod and S-27609
Testerman, T. L., Gerster, J. F., Imbertson, L. M., Reiter, M. J., Miller, R. L., Gibson, S. J., Wagner, T. L., & Tomai, M. A. (1995) · Journal of Leukocyte Biology · doi:10.1002/jlb.58.3.365 · Cited by 265
Wagner, T. L., Ahonen, C. L., Couture, A. M., Gibson, S. J., Miller, R. L., Smith, R. M., Reiter, M. J., Vasilakos, J. P., & Tomai, M. A. (1999) · Cellular Immunology · doi:10.1006/cimm.1998.1406 · Cited by 258
Tyring, S. K., Arany, I., Stanley, M. A., Tomai, M. A., Miller, R. L., Smith, M. H., McDermott, D. J., & Slade, H. B. (1998) · Journal of Infectious Diseases · doi:10.1086/517472 · Cited by 250
Self-citationSelf‐administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
Hengge, U. R., Esser, S., Schultewolter, T., Behrendt, C., Meyer, T., Stockfleth, E., & Goos, M. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03777.x · Cited by 232
Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts
Beutner, K. R., Tyring, S. K., Trofatter, K. F., Douglas, J. M., Spruance, S., Owens, M. L., Fox, T. L., Hougham, A. J., & Schmitt, K. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.789 · Cited by 225
Cytokine induction in mice by the immunomodulator imiquimod
Reiter, M. J., Tester man, T. L., Miller, R. L., Weeks, C. E., & Tomai, M. A. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.2.234 · Cited by 168
Harrison, C. J., Jenski, L. J., Voychehovski, T., & Bernstein, D. I. (1988) · Antiviral Research · doi:10.1016/0166-3542(88)90032-0 · Cited by 154
Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases
Stockfleth, E., Meyer, T., Benninghoff, B., & Christophers, E. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04197.x · Cited by 122
Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression.
Kono, T., Kondo, S., Pastore, S., Shivji, G. M., Tomai, M. A., McKenzie, R. C., & Sauder, D. N. (1994) · PubMed · Cited by 113
Stanley, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00013-8 · Cited by 33
Self-citationTopical imiquimod for recalcitrant facial flat warts.
Schwab, R. A., & Elston, D. M. (2000) · PubMed · Cited by 31
Kahn, J. A., & Bernstein, D. I. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000068036.26828.13 · Cited by 24
Cited by
Rubin, A. I., Chen, E. H., & Ratner, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044151 · Cited by 769
Mechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 732
Radiation dermatitis: Clinical presentation, pathophysiology, and treatment 2006
Hymes, S. R., Strom, E. A., & Fife, C. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.08.054 · Cited by 645
Toll-like receptors in immunity and inflammatory diseases: Past, present, and future
Vijay, K. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.002 · Cited by 643
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
Metadata
- Authors
- Stanley, M. A.
- Venue
- Clinical and Experimental Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10
- Volume
- 27
- Issue
- 7
- Pages
- 571-577
- ISSN
- 0307-6938 (ISSN-L)
- OpenAlex
- W2082669319
- Cited by
- 377
- References
- 22
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.